Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm<sup>3</sup>
<p>Abstract</p> <p>Background</p> <p>Antiretroviral therapy (ART) with a generic fixed-dose combination (FDC) of stavudine (d4T)/lamivudine (3TC)/nevirapine (NVP) is widely used in developing countries. The clinical data of this FDC among very advanced HIV-infected pati...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2007-03-01
|
Series: | AIDS Research and Therapy |
Online Access: | http://www.aidsrestherapy.com/content/4/1/6 |